Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Bevacizumab
Synonyms
Therapy Description

Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Bevacizumab Avastin VEGF Antibody 11 VEGFR Inhibitor (Pan) 36 Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
TP53 mutant Advanced Solid Tumor sensitive Bevacizumab Clinical Study - Cohort Actionable In a retrospective study, Avastin (bevacizumab) treatment was associated with increased progression-free survival in cancer patients carrying TP53 mutations (PMID: 23670029). 23670029
VHL loss renal cell carcinoma sensitive Bevacizumab Preclinical Actionable In a preclinical study, clear cell renal cell carcinoma xenograft models with VHL loss demonstrated sensitivity to Avastin (bevacizumab) (PMID: 22931246). 22931246

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01495988 Phase II Bevacizumab Vemurafenib Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma Terminated USA 0
NCT01132014 Phase I Bevacizumab Dacarbazine Autologous OC-DC Vaccine in Ovarian Cancer Completed USA 0
NCT03136406 Phase Ib/II GI-4000 Leucovorin Avelumab Nab-paclitaxel Bevacizumab Cyclophosphamide Capecitabine Oxaliplatin Fluorouracil ETBX-011 ALT-803 QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Unknown status USA 0
NCT02648711 Phase I NLG207 Bevacizumab Alternative Dosing for CRLX101 Alone and With Avastin in Advanced Solid Tumors Terminated USA 0
NCT01700400 Phase I Carboplatin Everolimus Bevacizumab Pemetrexed Disodium Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer Completed USA 0
NCT02521051 Phase Ib/II Bevacizumab Alectinib Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer Unknown status USA 0
NCT05284643 Phase 0 Bevacizumab Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma Recruiting USA 0
NCT04919629 Phase II Bevacizumab Bevacizumab + Pegcetacoplan + Pembrolizumab Pegcetacoplan + Pembrolizumab APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Recruiting USA 0
NCT01351415 Phase III Bevacizumab A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer Completed USA | ITA | FRA | ESP | DEU | BEL | AUT 11
NCT01390948 Phase II Temozolomide Bevacizumab A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma Completed ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS 6
NCT01532089 Phase II Bevacizumab Bevacizumab + Erlotinib Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations Completed USA 0
NCT02833701 Phase I Bevacizumab Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma Terminated USA 0
NCT02429843 Phase I Carboplatin + Paclitaxel Bevacizumab Carotuximab A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer Completed USA 0
NCT01730950 Phase II Bevacizumab Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma Completed USA 0
NCT02574078 Phase Ib/II Crizotinib + Nivolumab Erlotinib + Nivolumab Nivolumab + Pemetrexed Disodium Bevacizumab Carboplatin + Pemetrexed Disodium Bevacizumab + Nivolumab Nivolumab Erlotinib Carboplatin + Paclitaxel Carboplatin + Docetaxel Carboplatin + Nab-paclitaxel Carboplatin + Gemcitabine Paclitaxel Docetaxel Pemetrexed Disodium Gemcitabine A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370) Completed USA 0
NCT01516216 Phase II Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Study of Vitamin D in Untreated Metastatic Colorectal Cancer Completed USA 0
NCT01263782 Phase II Bevacizumab Carboplatin + Pemetrexed Disodium Cixutumumab BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer Completed USA 0
NCT01966003 Phase III Bevacizumab Bevacizumab-awwb Carboplatin + Paclitaxel Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer Completed USA | AUS 1
NCT01182350 Phase II Bevacizumab + Temozolomide Bevacizumab + Erlotinib + Temozolomide Bevacizumab + Erlotinib Bevacizumab Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) Terminated USA 0
NCT01648348 Phase Ib/II Carotuximab Bevacizumab Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Completed USA 0
NCT01743950 Phase II Bevacizumab A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab Recruiting USA 0
NCT02574663 Phase I Gemcitabine + Nab-paclitaxel Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Umbralisib TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors Completed USA 0
NCT02078648 Phase Ib/II SL-701 Poly ICLC Bevacizumab Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme Completed USA 0
NCT03220932 Phase III Bevacizumab Cisplatin Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer (HIPOVA-01) Unknown status FRA 0
NCT04017455 Phase II Bevacizumab Atezolizumab Atezolizumab + Bevacizumab Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN) (TARZAN) Recruiting 1
NCT05238831 Phase II Vemurafenib Vinorelbine Palbociclib Irinotecan Alpelisib Capecitabine Atezolizumab Paclitaxel Entrectinib Cobimetinib Nab-paclitaxel Fulvestrant Carboplatin Olaparib Pertuzumab/trastuzumab/hyaluronidase-zzxf Niraparib Vismodegib Alectinib Letrozole Ado-trastuzumab emtansine Bevacizumab Eribulin Anastrozole SMMART Adaptive Clinical Treatment (ACT) Trial Withdrawn 0
NCT01269853 Phase Ib/II Bevacizumab Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA Recruiting USA 0
NCT01814813 Phase II Bevacizumab Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Terminated USA 0
NCT01187199 Phase I Bevacizumab Paclitaxel Carboplatin Sorafenib Temsirolimus Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer Active, not recruiting USA 0
NCT01206530 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Bevacizumab Hydroxychloroquine FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer Completed USA 0
NCT01569984 Phase II Bevacizumab Radiosensitization of AVASTIN; (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis Completed CAN 0
NCT04787289 Phase II Bevacizumab A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer Recruiting CAN 0
NCT01954030 Phase Ib/II Bevacizumab Carboxyamidotriazole Orotate Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure Terminated USA 0
NCT01580969 Phase Ib/II Bevacizumab Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma Completed USA 0
NCT01894451 Phase I Bevacizumab Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy Completed USA 0
NCT02157103 Phase II Bevacizumab A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma Completed USA 0
NCT01788280 Phase I Bevacizumab Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab Withdrawn USA 0
NCT03387098 Phase Ib/II GI-4000 Leucovorin Nab-paclitaxel Bevacizumab Avelumab ALT-803 Fluorouracil ETBX-011 Oxaliplatin Aldoxorubicin Capecitabine Cyclophosphamide QUILT-3.070: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Unknown status USA 0
NCT01459380 Phase I Carboplatin Doxorubicin Veliparib Bevacizumab Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed USA 0
NCT01331616 Phase I Bevacizumab Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab Withdrawn 0
NCT01266031 Phase Ib/II Bevacizumab + Vorinostat Bevacizumab Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma Completed USA 0
NCT01727089 Phase II Bevacizumab Bevacizumab + Carotuximab Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer Completed USA | AUS 1
NCT02010606 Phase I Bevacizumab Temozolomide Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma Completed USA 0
NCT01765582 Phase II Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer Terminated USA 0
NCT01967810 Phase II Bevacizumab Paclitaxel Trevatide ANG1005 in Patients With Recurrent High-Grade Glioma Completed USA 0
NCT00602329 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Bevacizumab MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer Terminated USA 0
NCT01860638 Phase III Bevacizumab Lomustine A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma Completed ITA | GBR | FRA | ESP | CAN | AUT 9
NCT01454102 Phase I Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) Completed USA | CAN 0
NCT01356290 Phase II Thalidomide Fenofibrate Etoposide Bevacizumab Celecoxib Cyclophosphamide + Cytarabine Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT) Recruiting USA | FRA | ESP | AUT 4
NCT01803282 Phase I Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Completed USA 0
NCT03387085 Phase Ib/II ETBX-051 Aldoxorubicin ETBX-061 Cisplatin Cyclophosphamide haNK cells GI-4000 Bevacizumab ALT-803 Fluorouracil ETBX-011 Oxaliplatin Capecitabine Leucovorin GI-6301 Nab-paclitaxel Avelumab GI-6207 QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. Active, not recruiting USA 0
NCT01344824 Phase II Bevacizumab Erlotinib Carboplatin Pemetrexed Disodium Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers Completed USA 0
NCT04681677 Phase II Bevacizumab Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab (IORT) Recruiting USA 0
NCT01312376 Phase I Fludarabine Cyclophosphamide Bevacizumab CD3/CD28 stimulated/primed autologous Ts OC-DC vaccine Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer Terminated USA 0
NCT01625936 Phase I Bevacizumab NLG207 CRLX101 Plus Bevacizumab in Advanced RCC Completed USA 0
NCT03149003 Phase II Bevacizumab + DSP-7888 Bevacizumab A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD201G) Completed USA | CAN 3
NCT01578551 Phase II Metformin Carboplatin + Paclitaxel Bevacizumab A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. Terminated USA 0
NCT06011109 Phase Ib/II Bevacizumab APG-157 Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab Recruiting USA 0
NCT01933815 Phase Ib/II Bevacizumab TPI 287 Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma Suspended USA 0
NCT00879437 Phase II Bevacizumab Valproic acid Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas Completed USA 0
NCT01526837 Phase I Bevacizumab Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence Terminated USA 0
NCT02305758 Phase II Fluorouracil + Irinotecan + Leucovorin Bevacizumab Veliparib Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer Completed 0
NCT01937715 Phase II Bevacizumab Gedatolisib Fluorouracil + Irinotecan + Leucovorin A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer Terminated USA | ESP | CAN 0
NCT01107626 Phase III Pemetrexed Disodium Bevacizumab Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Completed USA 0
NCT04008030 Phase III Nivolumab Fluorouracil + Irinotecan + Leucovorin Cetuximab Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab Ipilimumab + Nivolumab A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 14
NCT01139723 Phase I Bevacizumab MINT1526A A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors Completed USA 0
NCT02285959 Phase I Bevacizumab Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme Recruiting USA 0
NCT02456857 Phase II Bevacizumab Everolimus Pegylated liposomal doxorubicin Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative Completed USA 0
NCT02743078 Phase II Bevacizumab Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma Terminated USA 0
NCT01811498 Phase Ib/II Bevacizumab Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM Completed USA 0
NCT01588184 Phase III Bevacizumab An Extension Study to Provide Continued Avastin Therapy to Patients With Solid Tumours Who Were Previously Enrolled in a Roche/Genentech Sponsored Study Completed ITA | GBR | FRA | ESP | DEU | CAN | AUT 14
NCT02754362 Phase II Poly ICLC Bevacizumab A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma Withdrawn USA 0
NCT01305213 Phase Ib/II Fosbretabulin Bevacizumab Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed USA 0
NCT03032484 Phase II Bevacizumab Bevacizumab + TVB-2640 TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma Completed USA 0
NCT01916447 Phase I Bevacizumab Trifluridine-tipiracil hydrochloride Irinotecan A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors. Completed USA 0
NCT02847559 Phase II Bevacizumab Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma Recruiting USA 0
NCT02138617 Phase II Leucovorin Bevacizumab Irinotecan Fluorouracil Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT01925573 Phase I Bevacizumab NOVOTTF-100A+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) Terminated USA 0
NCT01213238 Phase I Oxaliplatin Capecitabine Bevacizumab Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab Completed USA 0
NCT02606305 Phase I Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer Completed USA | ESP | CAN | BEL 0
NCT02413853 Phase II Bevacizumab PRI-724 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer Withdrawn USA 0
NCT01985763 Phase Ib/II Genistein Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Genistein in Treatment of Metastatic Colorectal Cancer Completed USA 0
NCT01327612 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab Open Label Extension Study of Conatumumab and AMG 479 Completed USA | ESP 1
NCT02698254 Phase 0 Bevacizumab Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy Active, not recruiting USA 0
NCT04299880 Phase I Gemcitabine + Nab-paclitaxel + Napabucasin Napabucasin Bevacizumab Napabucasin + Paclitaxel Napabucasin + Nivolumab Fluorouracil + Irinotecan + Leucovorin + Napabucasin Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols Completed USA | FRA 2
NCT02768389 Phase I Bevacizumab Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Completed USA 0
NCT02272413 Phase III Carboplatin + Paclitaxel Bevacizumab Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer Completed USA | ITA | GBR | ESP | DEU 23
NCT02661815 Phase I Paclitaxel + Ricolinostat Bevacizumab A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Terminated USA 0
NCT01067469 Phase II Bevacizumab Bevacizumab + Lomustine Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) Completed USA 0
NCT01061515 Phase I Capecitabine Bevacizumab Oxaliplatin Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Active, not recruiting USA 0
NCT01392209 Phase I Bevacizumab Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma Completed USA 0
NCT01588431 Phase II Cetuximab + Cisplatin + Docetaxel Bevacizumab Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer Completed USA 0
NCT02884648 Phase II Bevacizumab Bevacizumab in Ovarian Cancer Patients With Disease at Second-look Surgery Recruiting USA 0
NCT02017717 Phase III Nivolumab Bevacizumab Ipilimumab + Nivolumab A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 4
NCT02120287 Phase II Bevacizumab Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme Completed USA 0
NCT01898130 Phase II Bevacizumab Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy Completed USA 0
NCT05588388 Phase II Bevacizumab Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases (BELIEVE) Not yet recruiting USA 0
NCT00461773 Phase II Letrozole Bevacizumab Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer Terminated USA 0
NCT01445509 Phase I Bevacizumab Dasatinib Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors Completed USA 0
NCT02436993 Phase II Bevacizumab Pertuzumab + Trastuzumab Carboplatin + Paclitaxel Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting Active, not recruiting USA 0
NCT00565851 Phase III Gemcitabine Docetaxel + Paclitaxel Carboplatin Bevacizumab Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA 2
NCT01217931 Phase II Everolimus Pazopanib Bevacizumab Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy Active, not recruiting USA 0
NCT00968240 Phase I Bevacizumab Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) Completed USA 0
NCT01756352 Phase II Bevacizumab FET-PET for Evaluation of Response of Recurrent GBM to Avastin Completed USA 0
NCT04188145 Phase III Capecitabine Fluorouracil + Leucovorin Bevacizumab Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Capecitabine A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer (BEVAMAINT) Recruiting FRA 0
NCT01083966 Phase I Bevacizumab Intraarterial Cerebral Infusion of Avastin for Vestibular Schwannoma (Acoustic Neuroma) Suspended USA 0
NCT01201850 Phase I Bevacizumab The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors Terminated USA 0
NCT01015222 Phase I Methylnaltrexone Bromide Dasatinib Paclitaxel Bevacizumab Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies Completed USA 0
NCT03743662 Phase II Nivolumab Bevacizumab Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma Active, not recruiting USA 0
NCT01248949 Phase I Bevacizumab MEDI3617 Gemcitabine Carboplatin Paclitaxel A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors Completed USA 0
NCT03387111 Phase Ib/II Capecitabine Nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab ALT-803 Fluorouracil ETBX-011 Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy Unknown status USA 0
NCT01767792 Phase II Bevacizumab Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Completed USA 0
NCT05445778 Phase III Bevacizumab + Mirvetuximab Soravtansine Bevacizumab Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) Recruiting USA | ITA | GBR | ESP | CAN | BEL | AUS 4
NCT06160206 Phase II Bevacizumab + Retifanlimab Bevacizumab Retifanlimab With Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma Not yet recruiting USA 0
NCT00588770 Phase III Bevacizumab Cisplatin + Docetaxel Cisplatin + Fluorouracil Carboplatin + Docetaxel Carboplatin + Fluorouracil Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 2
NCT02511405 Phase III Bevacizumab VB-111 A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) Completed USA | CAN 1
NCT00378638 Phase II Bevacizumab Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer Unknown status USA 0
NCT01493843 Phase II Carboplatin Pictilisib Bevacizumab Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 8
NCT01894061 Phase II Bevacizumab NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma Completed USA 0
NCT03878524 Phase I Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) Terminated USA 0
NCT02490878 Phase II Dexamethasone Prednisone Bevacizumab Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases Terminated USA | CAN 0
NCT02663271 Phase II Bevacizumab TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma Terminated USA 0
NCT00828009 Phase II Cyclophosphamide Bevacizumab Paclitaxel Emepepimut-S Carboplatin BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed USA 0
NCT02446431 Phase I Cyclophosphamide Bevacizumab Temsirolimus Valproic acid Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence Recruiting USA 0
NCT03661723 Phase II Bevacizumab Pembrolizumab Bevacizumab + Pembrolizumab Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Active, not recruiting USA 0
NCT02420821 Phase III Bevacizumab Sunitinib Atezolizumab A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 13
NCT02974621 Phase II Bevacizumab Cediranib + Olaparib Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma Active, not recruiting USA 0
NCT00356031 Phase II Bevacizumab Bevacizumab and Radiation Therapy for Sarcomas Completed USA 0
NCT01197170 Phase I Erlotinib Everolimus Sorafenib Anastrozole Bevacizumab Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Completed USA 0
NCT01471054 Phase II Dexamethasone intravitreal implant Bevacizumab Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma Terminated USA 0
NCT01903330 Phase II Bevacizumab Cyclophosphamide Sargramostim ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme Active, not recruiting USA 0
NCT02414165 Phase II Bevacizumab Lomustine Toca 511 + Toca FC Temozolomide P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5) Terminated USA | CAN 2


Additional content available in CKB BOOST